142 related articles for article (PubMed ID: 35503397)
1. Targeting SMYD2 inhibits angiogenesis and increases the efficiency of apatinib by suppressing EGFL7 in colorectal cancer.
Zhang Y; Zhou L; Xu Y; Zhou J; Jiang T; Wang J; Li C; Sun X; Song H; Song J
Angiogenesis; 2023 Feb; 26(1):1-18. PubMed ID: 35503397
[TBL] [Abstract][Full Text] [Related]
2. SMYD2 epigenetically activates MEX3A and suppresses CDX2 in colorectal cancer cells to augment cancer growth.
Pan L; Fan Y; Zhou L
Clin Exp Pharmacol Physiol; 2022 Sep; 49(9):959-969. PubMed ID: 35637161
[TBL] [Abstract][Full Text] [Related]
3. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
[TBL] [Abstract][Full Text] [Related]
4. Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.
Zhang X; Tanaka K; Yan J; Li J; Peng D; Jiang Y; Yang Z; Barton MC; Wen H; Shi X
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17284-9. PubMed ID: 24101509
[TBL] [Abstract][Full Text] [Related]
5. The tale of two domains: proteomics and genomics analysis of SMYD2, a new histone methyltransferase.
Abu-Farha M; Lambert JP; Al-Madhoun AS; Elisma F; Skerjanc IS; Figeys D
Mol Cell Proteomics; 2008 Mar; 7(3):560-72. PubMed ID: 18065756
[TBL] [Abstract][Full Text] [Related]
6. The lysine methyltransferases SET and MYND domain containing 2 (Smyd2) and Enhancer of Zeste 2 (Ezh2) co-regulate osteoblast proliferation and mineralization.
Dashti P; van de Peppel J; Thaler R; Paradise CR; Stein GS; Montecino MA; van Leeuwen JPTM; van der Eerden BJ; Dudakovic A; van Wijnen AJ
Gene; 2023 Jan; 851():146928. PubMed ID: 36191822
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2.
Abu-Farha M; Lanouette S; Elisma F; Tremblay V; Butson J; Figeys D; Couture JF
J Mol Cell Biol; 2011 Oct; 3(5):301-8. PubMed ID: 22028380
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex.
Brown MA; Sims RJ; Gottlieb PD; Tucker PW
Mol Cancer; 2006 Jun; 5():26. PubMed ID: 16805913
[TBL] [Abstract][Full Text] [Related]
9. The histone methyltransferase Smyd2 is a negative regulator of macrophage activation by suppressing interleukin 6 (IL-6) and tumor necrosis factor α (TNF-α) production.
Xu G; Liu G; Xiong S; Liu H; Chen X; Zheng B
J Biol Chem; 2015 Feb; 290(9):5414-23. PubMed ID: 25583990
[TBL] [Abstract][Full Text] [Related]
10. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins.
Xu S; Zhong C; Zhang T; Ding J
J Mol Cell Biol; 2011 Oct; 3(5):293-300. PubMed ID: 21724641
[TBL] [Abstract][Full Text] [Related]
11. Histone methyltransferase SMYD2: ubiquitous regulator of disease.
Yi X; Jiang XJ; Fang ZM
Clin Epigenetics; 2019 Aug; 11(1):112. PubMed ID: 31370883
[TBL] [Abstract][Full Text] [Related]
12. SMYD2 Drives Mesendodermal Differentiation of Human Embryonic Stem Cells Through Mediating the Transcriptional Activation of Key Mesendodermal Genes.
Bai HJ; Zhang P; Ma L; Liang H; Wei G; Yang HT
Stem Cells; 2019 Nov; 37(11):1401-1415. PubMed ID: 31348575
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
Komatsu S; Ichikawa D; Hirajima S; Nagata H; Nishimura Y; Kawaguchi T; Miyamae M; Okajima W; Ohashi T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Imoto I; Inazawa J; Otsuji E
Br J Cancer; 2015 Jan; 112(2):357-64. PubMed ID: 25321194
[TBL] [Abstract][Full Text] [Related]
14. SMYD2 suppresses APC2 expression to activate the Wnt/β-catenin pathway and promotes epithelial-mesenchymal transition in colorectal cancer.
Meng F; Liu X; Lin C; Xu L; Liu J; Zhang P; Zhang X; Song J; Yan Y; Ren Z; Zhang Y
Am J Cancer Res; 2020; 10(3):997-1011. PubMed ID: 32266106
[TBL] [Abstract][Full Text] [Related]
15. Structure of human SMYD2 protein reveals the basis of p53 tumor suppressor methylation.
Wang L; Li L; Zhang H; Luo X; Dai J; Zhou S; Gu J; Zhu J; Atadja P; Lu C; Li E; Zhao K
J Biol Chem; 2011 Nov; 286(44):38725-38737. PubMed ID: 21880715
[TBL] [Abstract][Full Text] [Related]
16. Lysine methyltransferase SMYD2 promotes triple negative breast cancer progression.
Li LX; Zhou JX; Calvet JP; Godwin AK; Jensen RA; Li X
Cell Death Dis; 2018 Feb; 9(3):326. PubMed ID: 29487338
[TBL] [Abstract][Full Text] [Related]
17. SMYD2 overexpression is associated with tumor cell proliferation and a worse outcome in human papillomavirus-unrelated nonmultiple head and neck carcinomas.
Ohtomo-Oda R; Komatsu S; Mori T; Sekine S; Hirajima S; Yoshimoto S; Kanai Y; Otsuji E; Ikeda E; Tsuda H
Hum Pathol; 2016 Mar; 49():145-55. PubMed ID: 26826421
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of SET and MYND Domain-Containing Protein 2 (SMYD2) Is Associated with Tumor Progression and Poor Prognosis in Patients with Papillary Thyroid Carcinoma.
Xu W; Chen F; Fei X; Yang X; Lu X
Med Sci Monit; 2018 Oct; 24():7357-7365. PubMed ID: 30319138
[TBL] [Abstract][Full Text] [Related]
19. LLY-507, a Cell-active, Potent, and Selective Inhibitor of Protein-lysine Methyltransferase SMYD2.
Nguyen H; Allali-Hassani A; Antonysamy S; Chang S; Chen LH; Curtis C; Emtage S; Fan L; Gheyi T; Li F; Liu S; Martin JR; Mendel D; Olsen JB; Pelletier L; Shatseva T; Wu S; Zhang FF; Arrowsmith CH; Brown PJ; Campbell RM; Garcia BA; Barsyte-Lovejoy D; Mader M; Vedadi M
J Biol Chem; 2015 May; 290(22):13641-53. PubMed ID: 25825497
[TBL] [Abstract][Full Text] [Related]
20. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J; Wan F; Zhang J; Zheng S; Yang Y; Hong Z; Dai B
Mol Carcinog; 2023 Jul; 62(7):940-950. PubMed ID: 37036190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
